http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-929054-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-32
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-28
filingDate 1962-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_213cdb885e8be3837818321334b14b2c
publicationDate 1963-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GB-929054-A
titleOfInvention Improvements in and relating to heterocyclic compounds and the manufacture thereof
abstract The invention comprises benzenesulphonyl ureas of the formula <FORM:0929054/IV(a)/1> wherein X and X1 are hydrogen, halogen, e.g. Cl, Br or F, or C1-4 alkyl or alkoxy groups, R is hydrogen or a C1-4 alkyl group and R1 is a C1-4 alkyl group and pharmacologically acceptable acid addition salts thereof; and their preparation by (a) reacting a benzenesulphonyl-urethane with a 1-aminopiperidine; (b) reacting a benzenesulphonylisocyanate with a 1-amino-piperidine; (c) reacting a benzenesulphonyl-urea with a 1-amino-piperidine; (d) reacting a benzenesulphonyl-carbamic halide with a 1-aminopiperidine; (e) reacting a benzenesulphonamide or an alkali-metal salt thereof with a piperidino-isocyanate; (f) reacting a benzenesulphonamide or an alkali-metal salt thereof with a piperidino-carbamoyl halide; (g) reacting an O-methyl-piperidino-isourea with a benzenesulphonyl halide and hydrolysing the resulting product; (h) reacting a benzenesulphonyl-cyanamide with a 1-amino-piperidine and hydrolysing the resulting guanidine; (i) reacting an alkali-metal salt of a benzenesulphonamide with a piperidino-isothiocyanate and oxidising the resulting thiourea or (j) reacting a piperidinourethane with an aryl sulphonamide. The products may be converted into their salts with acids such as hydrochloric, hydrobromic sulphuric, phospheric, tartaric, acetic, citric, succinic, maleic, benzoic and salicylic. Starting materials. 1-Amino-4-alkylpiperidines and 1-amino-4,4-dialkylpiperidines are made by treating the appropriate piperidine with nitrous acid and reducing the resulting 1-nitroso-4-alkyl (or 4,4-dialkyl)-piperidine. 4-Methyl-piperidino-isocyanate is prepared from 1-amino-4-methylpiperidine and phosgene. Pharmaceutical preparations, suitable for the treatment of diabetes, comprise the above compounds of the invention in admixture with a pharmaceutical carrier, preferably for oral administration, but also if desired for intravenous administration in a liquid carrier. The preparations may suitably take the form of capsules, tablets, powders, pills, solutions and suspensions. Specification 808,071 is referred to.
priorityDate 1962-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421019667
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID243
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454031256
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7370
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3733587
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432342465
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16658
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3520
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID76096
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID59917385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420314932
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414025555
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483880
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2723790
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1176
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID269655
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419546714
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419484158
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422148949
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24529
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415915112
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID118791
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19377747
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID338
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415922805
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559481
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558919
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6371
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54171524
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID286212
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415758710
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8082
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415949209
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558836
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451094705
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559377
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527900
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424592880
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID350013
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID129936144

Total number of triples: 52.